Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nuclear radioprotection therapeutic - Medesis Pharma

Next Previous
X
Search
Drug Profile

Nuclear radioprotection therapeutic - Medesis Pharma

Latest Information Update: 28 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medesis Pharma SA
  • Class Radioprotectives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute radiation syndrome

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Acute-radiation-syndrome in France (PO)
  • 01 Apr 2021 Nuclear radioprotection therapeutic is available for licensing as of 01 Apr 2021. https://www.medesispharma.com/corporate/vision/
  • 01 Apr 2021 Medesis Pharma has patent protection for AONYS® in Australia, Canada, China, Eurasia, Hong Kong, India, Israel, Japan, South Africa, USA (Medesis Pharma website, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top